611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Cancer
Resources
Basic InformationLatest News
Too Little Vitamin D Could Raise Colon Cancer Risk in Black WomenTargeted High-Dose Radiation Helps Fight Advanced Lung CancerCancer Costs U.S. Patients $21 Billion a YearWhy Are Cases of Pancreatic Cancer Rising in Young Women?Quit Smoking Before 45 & Wipe Out 87% of Lung Cancer RiskJust 5 Hours of Moderate Exercise a Week Cuts Your Cancer RiskWhen Cancer Strikes, Who's at Higher Risk for Suicide?Powell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsTreating Depression Could Lengthen Lung Cancer Patients' LivesResearchers Find Better Way to Fight Breast Cancer That Has Spread to BrainCancer Care Costs U.S. $156 Billion Per Year; Drugs a Major FactorNearly Half of U.S. Breast Cancer Patients Use Pot or CBD; Many Don't Tell DoctorsAnti-Nausea Drug May Boost Survival for Some Cancer PatientsYour Free Cancer Screen Shows Trouble: What If You Can't Afford the Follow-Up?Access to Top Drugs Makes the Difference for Black Lung Cancer PatientsWhy Skin Cancer Checks Are Even More Important for Hispanic People1 in 7 Cancer Patients Worldwide Missed a Surgery Due to PandemicAI Helps Rule Out Cancer in Women With Dense BreastsExisting Drugs Could Treat Lung Cancer in NonsmokersColon Cancer Diagnoses Fell 40% in Pandemic, and That's Not Good NewsRacial Disparities Persist With Childhood CancersNew Tests for Colon, Prostate Cancer Show PromiseTough Choices: Chemo That Can Save Kids With Cancer Can Also Damage HearingCan a Computer Program Help Docs Spot Breast Cancer?Trials Show COVID Vaccines Well Worth It for Cancer PatientsCancer in Hispanics: Good News and BadRadiation Therapy for Breast Cancer May Have Long-Term Risk for the HeartCommon Form of Liver Cancer on the Rise in Rural AmericaNew Drug Combo Boosts Survival Against Aggressive Form of Breast CancerPeople With MS Have Worse Survival If Colon Cancer StrikesHaving Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyYour State's Laws Might Save Your Life If Breast Cancer Strikes9/11 First Responders Face Higher Cancer Risk 20 Years LaterChild Cancers Are Rare, But Here Are Signs to Look ForIn Cancer Patients, COVID Vaccine Immunity at 6 Months Is Similar to General PopulationWhich Cancer Patients Need a COVID Booster Shot Most?AI May Not Be Ready to Accurately Read MammogramsToo Many Antibiotics Might Raise Colon Cancer RiskPandemic Brought Big Drop in Breast Cancer Screening in Older, Low-Income WomenFewer American Adults Are Getting Malignant Brain TumorsDon't Forget to Apply Sunscreen Before & After Water FunExercise Could Help Fight 'Chemo Brain' in Breast Cancer PatientsSpotting the Signs of Deadly Melanoma Skin CancersVitamin D Might Help Prevent Early-Onset Colon CancerFar Too Few People of Color in U.S. Pancreatic Cancer TrialsDeath of Spouse Could Raise Men's Odds for Prostate CancerCancer Patients Avoiding Pot, Even as Rules on Use RelaxOne Key Question Can Help Spot Skin CancerImmune-Based Therapy May Help Some Battling Advanced Colon Cancers
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

New Drug Might Be Non-Surgical Option for Common Skin Cancers

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Aug 9th 2021

new article illustration

MONDAY, Aug. 9, 2021 (HealthDay News) -- An experimental gel has shown early promise in treating the most common form of skin cancer — hinting at a potential alternative to surgery in the future.

Researchers tested the gel in 30 patients with basal cell carcinoma (BCC), a skin cancer diagnosed in more than 3 million Americans each year. The tumors rarely spread and are highly curable, usually through surgical removal.

Even so, non-surgical options are needed, said senior researcher Dr. Kavita Sarin, an associate professor of dermatology at Stanford University, in Redwood City, Calif.

In some cases, for example, the skin cancer may be located in an area — like the face — where surgery could leave scarring that patients want to avoid. Plus, Sarin said, many people develop multiple basal cell carcinomas over time, which means returning for repeat surgeries.

A couple of topical medications are approved for BCC, but only for "superficial" cancers, which account for a minority of cases, Sarin said.

For the new study, her team tested an experimental topical drug called remetinostat, which blocks an enzyme known as histone deacetylase. Lab research has shown that inhibiting the enzyme can suppress BCC growth.

The study — published Aug. 6 in Clinical Cancer Research — was a small mid-stage trial, designed to see whether the topical medication worked at all.

And for most of the patients, Sarin's team found, it did: Of 33 skin cancers treated for six weeks, 17 completely resolved, and six more partially responded — meaning they shrunk by at least 30% in diameter.

The gel seemed most effective against superficial BCC, with all of those skin tumors shrinking or disappearing, the researchers found. But about two-thirds of other tumor types responded, too — including nodular BCC, the most common form of the cancer, and "infiltrative" tumors, which can invade the skin more deeply and widely.

The main side effect was a rash at the application site.

Sarin said further studies are needed to "optimize" the treatment regimen, which in this trial was three daily applications of the gel, for six weeks.

"This was a small pilot study just to see whether there's efficacy," she noted.

Then there is the question of how long the effects last. "The durability of the treatment will be the main question going forward," Sarin said.

The initial results are promising, according to Dr. Jeffrey Weinberg, an associate clinical professor of dermatology at Icahn School of Medicine at Mount Sinai, in New York City.

"Obviously we need more data," said Weinberg, who was not involved in the research. "But this certainly is an advance."

He added that the effects on the infiltrative tumors — with two of three responding completely — were "impressive."

A disadvantage of a topical gel versus surgery, Weinberg noted, is that there is no way to know if the tumor really has been completely cleared.

In this trial, the researchers did surgical excisions after the treatment period ended, and verified that 17 tumors had completely resolved. But in the "real world," where topical treatment would be used as a surgery alternative, that's not going to happen, Weinberg pointed out.

Still, he said, some people with BCC are not candidates for surgery, while others would prefer to avoid it, so an additional, effective topical option would be welcome.

Sarin said, "I'm optimistic that in the future we'll be able to treat this more as a nuisance than as a cancer that has to be treated surgically."

The study was partly funded by Medivir, the Swedish biotech company developing remetinostat.

More information

The Skin Cancer Foundation has more on treating basal cell carcinoma.

SOURCES: Kavita Sarin, MD, PhD, associate professor, dermatology, Stanford University School of Medicine, Redwood City, Calif.; Jeffrey Weinberg, MD, associate clinical professor, dermatology, Icahn School of Medicine at Mount Sinai, New York City; Clinical Cancer Research, Aug. 6, 2021, online